0B68 Rui, Hallgeir - Thomas Jefferson University - Thomas Jefferson University

Hallgeir Rui, MD, PhD

Contact Dr. Rui

Kimmel Cancer Center
233 S. Tenth Street, Suite 322
Philadelphia, PA 19107

(215) 503-9259
(215) 503-9246 fax

Most Recent Peer-reviewed Publications

  1. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
  2. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
  3. Inflammatory signaling compromises cell responses to interferon alpha
  4. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression
  5. Reply to A. Italiano
  6. Differential expression of arrestins is a predictor of breast cancer progression and survival
  7. Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma
  8. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure
  9. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer
  10. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer
  11. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells
  12. Protocol for constructing tissue arrays by cutting edge matrix assembly.
  13. Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation
  14. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells
  15. Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling
  16. RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response
  17. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients
  18. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence
  19. Prolactin inhibits BCL6 expression in breast cancer through a stat5a-dependent mechanism
  20. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes